Astrazeneca plc NASDAQ:AZN Price, Chart, News & Insight

NASDAQ:AZN

AstraZeneca Gains as Analysts Remain Constructive on Long-Term Outlook

Shares of AstraZeneca (AZN) rose about 1% as investors responded positively to continued support from Wall Street analysts and the company's strong position within the global pharmaceutical industry.

Several major research firms reiterated their ratings on the stock, with both JPMorgan and Jefferies maintaining positive Buy recommendations. While Deutsche Bank kept a more cautious Sell rating, the overall tone of analyst commentary remained broadly supportive, reflecting confidence in AstraZeneca's diversified portfolio and long-term growth prospects.

Investor sentiment toward AstraZeneca continues to be supported by the company's strong lineup of oncology, cardiovascular, rare disease, and respiratory treatments. The company has established itself as one of the fastest-growing large pharmaceutical firms in recent years, driven by successful drug launches and expanding global market penetration.

Analysts also remain focused on AstraZeneca's robust pipeline, which includes multiple late-stage development programs that could provide additional growth opportunities over the coming years. Continued innovation in cancer therapies remains a key driver of the bullish investment case.

The stock's modest gain suggests investors are viewing AstraZeneca as a relatively defensive growth opportunity at a time when broader market uncertainty remains elevated. Healthcare stocks often attract interest during periods of economic volatility, and AstraZeneca's combination of recurring revenue, strong cash generation, and pipeline potential continues to appeal to long-term investors.

While analyst opinions remain somewhat mixed, today's positive share performance indicates that investors are placing greater weight on the company's durable earnings profile and future growth opportunities than on the more cautious views expressed by a minority of analysts.

💬 🔗

Global Finance News 06-09-26

AstraZeneca Beats Estimates in Q1 2026 as Oncology Surge Powers Revenue Above $15 Billion
April 29, 2026 | NYSE: AZN

AstraZeneca delivered a strong first quarter on Wednesday, posting total revenue of $15.29 billion — up 13% year-on-year and ahead of the $14.94 billion consensus — while core EPS of $2.58 beat analyst expectations of $2.51–$2.53, per Benzinga and CNBC. Despite the double beat, shares slipped, reflecting broader investor caution around US drug pricing policy rather than any fundamental concern with the results.

Oncology drove the performance, rising 20% year-on-year to $6.79 billion — 45% of total product revenue — with Imfinzi (+34%), Enhertu (+40%), Calquence (+21%), and Tagrisso (+9%) all posting strong gains, per Benzinga. Rare Disease also delivered double-digit growth, while cardiovascular and renal revenues declined 7% at constant currency due to foreign exchange headwinds, per the official company release.

On the pipeline, AstraZeneca reported positive Phase III readouts for four high-value programmes since its Q4 2025 results, including first pivotal data for two new molecular entities — tozorakimab in COPD and efzimfotase alfa in hypophosphatasia. Citi called AstraZeneca "the fastest growth and best pipeline in the sector," with 11 further late-stage readouts still expected in 2026, per CNBC.

For the full year, the company reconfirmed guidance of mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates, per the official results.

💬 🔗

WS Investor 04-29-26

AstraZeneca announced that its inhaled therapy Breztri Aerosphere has been approved in the United States for the maintenance treatment of asthma in patients aged 12 and older.

The approval makes Breztri the first and only triple-combination inhaler therapy for asthma, expanding its use beyond COPD. Clinical trials showed significant improvements in lung function and rapid onset of action compared to dual therapies.

The decision addresses a major unmet need, as many asthma patients remain uncontrolled on existing treatments, and marks a key milestone in respiratory care innovation.

Source: AstraZeneca

💬 🔗

The Investor 04-28-26

AstraZeneca reported positive Phase III trial results showing that its immunotherapy combination significantly improves outcomes in early-stage liver cancer.

In the EMERALD-3 trial, the combination of Imfinzi (durvalumab), Imjudo (tremelimumab), lenvatinib, and transarterial chemoembolisation (TACE) achieved a statistically significant improvement in progression-free survival compared to TACE alone.

The treatment also demonstrated a trend toward improved overall survival, a key secondary endpoint, although further data are still being evaluated.

The regimen, known as STRIDE, combines dual immunotherapy with targeted therapy and a standard embolisation procedure, aiming to delay disease progression and recurrence in patients with unresectable hepatocellular carcinoma.

AstraZeneca stated that the safety profile was consistent with known data and that the results will be presented at a future medical meeting and submitted to global regulators.

The findings highlight the potential of earlier use of immunotherapy combinations to improve outcomes in liver cancer, a disease where many patients currently face progression within months after standard treatment.

💬 🔗

The Investor 04-02-26

AstraZeneca announced positive Phase III clinical trial results for its investigational therapy efzimfotase alfa (ALXN1850), targeting the rare bone disease hypophosphatasia (HPP).

The global clinical program showed strong results in pediatric patients, with the MULBERRY trial meeting its primary endpoint and demonstrating significant improvements in bone health. The CHESTNUT trial also confirmed favorable safety and tolerability in children switching from existing treatments.

In adolescents and adults, the HICKORY trial did not meet its primary endpoint overall, but showed meaningful benefits in certain subgroups, including improvements in mobility, fatigue, and pain.

Overall, the therapy demonstrated a favorable safety profile across studies and may offer a more convenient dosing regimen compared to current treatments, with the potential to reshape care for this rare disease pending regulatory review.

💬 🔗

The Investor 03-31-26

AstraZeneca announced that its investigational drug Tozorakimab met primary endpoints in two Phase III trials (OBERON and TITANIA) for chronic obstructive pulmonary disease (COPD).

The studies showed that tozorakimab significantly reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo, across both former smokers and the broader patient population. The treatment was also reported to be well tolerated with a favorable safety profile.

Tozorakimab is a potential first-in-class therapy targeting interleukin-33 (IL-33), designed to reduce inflammation and address mucus dysfunction—key drivers of COPD progression.

The results mark the first successful Phase III confirmation for an IL-33–targeting biologic in COPD, a disease affecting nearly 400 million people globally. AstraZeneca plans to present detailed data at upcoming medical conferences while continuing additional late-stage trials.

💬 🔗

The Investor 03-27-26

AstraZeneca reported strong full-year and fourth-quarter 2025 results, supported by broad-based commercial growth and robust pipeline progress. FY 2025 total revenue rose 8% at constant exchange rates to $58.7 billion, driven by Oncology, CVRM, Respiratory & Immunology, and Rare Disease, with growth across all major regions. Core operating profit increased 9%, while core EPS climbed 11% to $9.16. Reported EPS rose 45% to $6.60.

In Q4 2025, total revenue increased 2% at constant exchange rates to $15.5 billion, with product sales up 7%. Reported EPS grew 47% to $1.50, while core EPS was broadly flat at $2.12. The company declared a second interim dividend of $2.17 per share, bringing the full-year dividend to $3.20, up 3% year on year.

During the past twelve months, AstraZeneca delivered 16 positive Phase 3 readouts and secured 43 approvals in major regions, bringing its total to 16 blockbuster medicines. CEO Pascal Soriot said momentum is continuing into 2026, with more than 20 Phase 3 readouts expected this year and over 100 Phase 3 trials ongoing, including a growing number using transformative technologies.

Separately, AstraZeneca’s ordinary shares began trading on the New York Stock Exchange on February 2, creating a harmonised listing across London, New York and Stockholm.

💬 🔗

WS Investor 02-10-26

AstraZeneca said the US Food and Drug Administration has issued a complete response letter for the biologics license application covering subcutaneous administration of Saphnelo in systemic lupus erythematosus, but the company has already submitted the requested information and is working with regulators to advance the review.

The company expects an FDA decision in the first half of 2026, while intravenous Saphnelo remains commercially available. The update follows positive Phase III TULIP-SC trial results and comes after the European Union approved the subcutaneous formulation in December 2025, reinforcing AstraZeneca’s confidence in the therapy’s safety and efficacy profile.

💬 🔗

The Investor 02-05-26

AstraZeneca said its immunotherapy Imfinzi (durvalumab) has been recommended for approval in the European Union as part of a perioperative treatment regimen for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. The positive opinion from the European Medicines Agency’s CHMP is based on results from the Phase III MATTERHORN trial, which showed a 29% reduction in the risk of disease progression, recurrence or death and a 22% reduction in the risk of death compared with chemotherapy alone.

If approved, the Imfinzi-based regimen would become the first immunotherapy-based perioperative treatment for this patient population in the EU, potentially setting a new standard of care in early gastric and gastroesophageal cancers.

💬 🔗

Global Finance News 02-02-26

AstraZeneca has agreed a major strategic collaboration with CSPC Pharmaceutical Group to expand its pipeline in obesity and type 2 diabetes, securing access to eight next-generation programmes and advanced drug-discovery technologies.

Under the agreement, AstraZeneca will obtain exclusive global rights outside China to CSPC’s once-monthly injectable weight management portfolio, including a clinical-ready asset, SYH2082, a long-acting GLP-1/GIP dual agonist set to enter Phase I trials, along with three additional preclinical candidates. The collaboration also gives AstraZeneca access to CSPC’s AI-driven peptide discovery platform and its proprietary LiquidGel monthly dosing technology, aimed at improving treatment adherence and convenience.

AstraZeneca will pay CSPC an upfront $1.2 billion, with potential development and regulatory milestones of up to $3.5 billion, plus sales milestones and tiered royalties. CSPC will advance the initial programmes through Phase I, after which AstraZeneca will lead further development and commercialisation outside China, while CSPC retains rights in China and selected territories.

The deal strengthens AstraZeneca’s weight management portfolio alongside existing assets such as elecoglipron and several injectable metabolic therapies, reflecting the company’s ambition to address obesity as a chronic, multifactorial disease with more convenient and scalable treatment options.

💬 🔗

Global Finance News 01-30-26

04-29-25WS News

04-14-25Global Finance News

04-09-25WS Investor

01-15-25WS News

NASDAQ:AZNFollow

NASDAQ:AZN